Nanocarriers and nonviral methods for delivering antiangiogenic factors for glioblastoma therapy: the story so far

Angiogenesis, the formation of new blood vessels, is an essential component of glioblastoma (GB) progression. The development of angiogenesis inhibitor therapy, including treatments targeting vascular endothelial growth factor (VEGF) in particular, raised new hopes for the treatment of GB, but no Ph...

Descripción completa

Detalles Bibliográficos
Autores principales: Clavreul, Anne, Pourbaghi-Masouleh, Milad, Roger, Emilie, Menei, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461002/
https://www.ncbi.nlm.nih.gov/pubmed/31040671
http://dx.doi.org/10.2147/IJN.S194858

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461002/
https://www.ncbi.nlm.nih.gov/pubmed/31040671
http://dx.doi.org/10.2147/IJN.S194858

Ejemplares similares